Sertraline Hydrochloride Form I is a defined crystalline polymorphic form of Sertraline Hydrochloride, a selective serotonin reuptake inhibitor (SSRI) pharmaceutical active ingredient. Sertraline Hydrochloride is widely used in pharmaceutical formulations for the management of major depressive disorder and several anxiety-related and obsessive-compulsive conditions. Form I is particularly important in API manufacturing because the crystalline form can influence solid-state properties, stability, processing and pharmaceutical performance.
Sertraline Hydrochloride has CAS Number 79559-97-0, molecular formula C17H18Cl3N and molecular weight 342.69 g/mol. The API contains the therapeutically active (1S,4S)-cis stereochemical configuration. USP defines Sertraline Hydrochloride at 97.0–102.0% on an anhydrous basis, while the current pharmacopoeial framework also controls the undesired (R,R) stereoisomer and several process-related organic impurities.
Form I is one of several known crystalline polymorphs of Sertraline Hydrochloride. The original polymorph patent identifies Form I as the most stable polymorph and describes its characteristic crystalline structure using X-ray diffraction. The patent reports a melting point of approximately 219°C for Form I.
Polymorphic control is important because different crystal forms can exhibit different physical characteristics even though they have the same chemical composition. For Sertraline Hydrochloride, Form I can therefore be identified and monitored using solid-state analytical techniques such as XRPD together with conventional chemical identification methods.
Sertraline Hydrochloride is the hydrochloride salt of the selective serotonin reuptake inhibitor Sertraline. The active pharmaceutical substance is a synthetic naphthalenamine derivative containing two chlorine atoms and one hydrochloride equivalent. It is described pharmacopoeially as a white or almost white crystalline powder and is slightly soluble in water, while its solubility in organic solvents varies with the solvent system.
The API is characterized by infrared spectroscopy, chromatographic retention, chloride identification and chromatographic purity testing. Optical purity is also important because the therapeutically active cis stereoisomer must be distinguished from the corresponding (R,R) isomer.
Sertraline Hydrochloride is an established SSRI pharmaceutical ingredient. It is used in formulations for depression and several psychiatric disorders, including obsessive-compulsive disorder, panic disorder and post-traumatic stress disorder. Its pharmacological action results primarily from inhibition of neuronal serotonin reuptake, increasing serotonergic activity in the central nervous system.
For pharmaceutical manufacturing, control of the correct stereochemical and polymorphic form is important because both chemical identity and solid-state characteristics contribute to consistent API quality.
Sertraline Hydrochloride has a well-established pharmacopoeial analytical framework. The current USP specification requires an assay of 97.0–102.0% calculated on the anhydrous basis. USP also specifies residue on ignition of NMT 0.3%, water of NMT 0.50%, and a specific limit of NMT 1.5% for the (R,R) Sertraline Hydrochloride stereoisomer.
The current USP organic-impurity procedure controls several named impurities, including 2,3-isosertraline, 4-deschlorosertraline, 3-deschlorosertraline, mandelic acid and the trans-R,S/trans-S,R related compounds. Depending on the manufacturing route, an alternative impurity procedure controls additional process impurities and total impurities.
Manufacturing Form I requires control not only of chemical purity but also of the crystalline polymorphic state. API quality programs can therefore combine HPLC assay and related-substance testing with XRPD or other validated solid-state characterization techniques.
A complete pharmaceutical API documentation package may include Certificate of Analysis, assay data, organic impurity profile, stereochemical purity, water content, residue on ignition, polymorphic-form characterization, residual-solvent data and stability information.
USP specifies preservation of Sertraline Hydrochloride in tight, light-resistant containers at a temperature not exceeding 40°C. For Form I API, packaging should also protect the material from conditions that could influence moisture content or solid-state stability.
Typical documentation can include Certificate of Analysis, specification sheet, analytical methods, HPLC chromatograms, impurity profile, stereochemical purity data, XRPD/polymorphism data, residual-solvent information, stability results and applicable GMP documentation.
Sertraline Hydrochloride Form I combines an established pharmacopoeial API identity with a defined crystalline form. Its quality requires accurate control of assay, stereochemical purity, organic impurities, water, residue on ignition and polymorphic form. Form I characterization is therefore an important component of quality-focused Sertraline Hydrochloride API manufacturing.
| Parameter | Specification |
|---|---|
| Appearance | white to off-white crystalline powder |
| Identification | IR & HPLC compliant |
| Assay (HPLC) | 98.0% – 102.0% |
| Residue on Ignition | NMT 0.30% |
| Total Impurities | NMT 0.50% |
| Water Content | NMT 0.50% |
| Specific Rotation | +38.8° to +43.0°, anhydrous substance, 25°C |
| Melting Point | Approximately 219°C |